FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Frontiers Syzygium aromaticum (clove buds) as a natural antibacterial agent: a promising alternative to combat multidrug resistant bacteria FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner BPC 157 Banned: Key Facts on the Latest FDA Decision